How Do You Spell BCR ABL PROTO ONCOGENE?

Pronunciation: [bˌiːsˌiːˈɑːɹ ˈabə͡l pɹˈə͡ʊtə͡ʊ ˈɒnkə͡ʊd͡ʒˌiːn] (IPA)

The spelling of "bcr abl Proto Oncogene" can be a bit tricky to understand. The word "bcr" is pronounced as /biː siː ɑːr/, with the "b," "c," and "r" each pronounced separately. "Abl" is pronounced as /æbl/ with a short "a" sound and a silent "e." Finally, "Proto Oncogene" is pronounced as /ˈprəʊtəʊ ˈɒŋkəʊdʒiːn/ with stress on the first syllable of "Proto" and "Oncogene." Understanding these pronunciations will make it easier to spell and remember these scientific terms accurately.

BCR ABL PROTO ONCOGENE Meaning and Definition

1. The BCR-ABL proto-oncogene refers to a genetic anomaly resulting from a reciprocal chromosomal translocation between the breakpoint cluster region (BCR) gene on chromosome 22 and the ABL proto-oncogene on chromosome 9. This translocation is commonly associated with a type of cancer known as chronic myeloid leukemia (CML).

   Normally, the BCR gene regulates cell growth, differentiation, and adherence. Similarly, the ABL gene encodes a protein tyrosine kinase involved in various cellular functions. However, the translocation in CML causes the fusion of these two genes, resulting in the formation of a hybrid BCR-ABL gene.

   The BCR-ABL gene produces a fusion protein, also called BCR-ABL, which possesses enhanced tyrosine kinase activity. This increased activity disrupts the balance of cellular proliferation and differentiation, leading to uncontrolled growth of bone marrow cells characteristic of CML. The BCR-ABL hybrid protein activates numerous signaling pathways involved in cell survival, proliferation, and inhibition of DNA repair mechanisms.

   The identification of the BCR-ABL fusion gene has had significant clinical implications. It has enabled the development of targeted therapy drugs known as tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, and nilotinib. These drugs specifically inhibit the overactive protein kinase activity of BCR-ABL, leading to improved outcomes and increased overall survival rates in CML patients. Understanding the molecular mechanism of BCR-ABL and the development of targeted therapies has revolutionized the treatment of CML and inspired similar approaches for other cancers driven by specific genetic abnormalities.

Common Misspellings for BCR ABL PROTO ONCOGENE

• vcr abl proto oncogene
• ncr abl proto oncogene
• hcr abl proto oncogene
• gcr abl proto oncogene
• bxr abl proto oncogene
• bvr abl proto oncogene
• bfr abl proto oncogene
• bdr abl proto oncogene
• bce abl proto oncogene
• bcd abl proto oncogene
• bcf abl proto oncogene
• bct abl proto oncogene
• bc5 abl proto oncogene
• bc4 abl proto oncogene
• bcr zbl proto oncogene
• bcr sbl proto oncogene
• bcr wbl proto oncogene
• bcr qbl proto oncogene
• bcr avl proto oncogene
• bcr anl proto oncogene